

**Information for Connecticut Prescribing Practitioners or  
Pharmacists of Legend Drugs**

- The information contained in this notice is being provided to Connecticut prescribing practitioners and pharmacists pursuant to Connecticut Public Act No. 23-171. This document contains the “list price” also known as the wholesale acquisition cost (“WAC”) of the prescription drug Elzonris® marketed by Stemline Therapeutics, Inc. (“Stemline”). The information is accurate as of the date of this notice.
- The price listed below is the WAC price, established and made available to the public by a third-party publisher. The WAC price represents Stemline’s published list price for the product sold to wholesalers, before any discount, rebate, or other price reduction. The WAC price listed may differ significantly from actual prices paid by customers and consumers. In addition, a product’s WAC is typically not associated with per-dose pricing, and do not necessarily reflect price per dosage, price per course of treatment or the cost effectiveness of all the products listed.
- Please refer to the product’s FDA-approved label and indication for further information.

**WAC of Stemline Marketed Products**

<b>NDC-11</b>	<b>Drug Name and Description</b>	<b>WAC</b>
72187-0401-01	Elzonris® [tagraxofusp-erzs], 10 mcg injection; single-dose, sterile glass vial containing 1 mL of solution	\$33,756.65

The information contained in this notice is accurate as of February 2025. For additional drug and price information see: <https://www.elzonris.com/>